Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 217 results

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)

PAR
Friday, November 19, 2021
Saturday, February 3, 2024
333
PAR-22-073

Funding Opportunity Purpose

Through this I-Corps at NIH program Funding Opportunity Announcement (FOA), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.

Limited Competition: Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Clinical Coordinating Center (CCC) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-014

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The CCC will facilitate implementation of clinical trials and will promote high quality and efficient timeliness in trial execution through such methods as master trial agreements and a central Institutional Review Board. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Limited Competition: Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Data Coordinating Center (DCC) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-013

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) for Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The DCC will have responsibility for data management, data quality, statistical analysis, Data Safety Monitoring Board(s) (DSMB) and reporting to regulatory and oversight groups. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network Clinical Center (Hub) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-015

Funding Opportunity Purpose

(Reissue of RFA-NS-16-016) The purpose of this funding opportunity announcement (FOA) is to invite applications from new and existing sites to serve as Clinical Centers (Hubs) in the SIREN Network. SIREN conduct of several multi-center Phase III clinical trials, to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and traumatic conditions. SIREN is made up of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and 11 clinical centers (Hubs). A Hub is usually an academic center or tertiary referral center which actively enrolls patients into all of the clinical trial performed in SIREN. Hubs also provide scientific leadership and administrative oversight to their multiple satellite sites ("Spokes"). Together the Hub and Spokes provide access to a large and varying patient population for clinical trials. SIREN performs a number of simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials are meritorious, peerreviewed projects which are awarded under separate funding announcements.

Notice of Special Interest (NOSI): Administrative Supplements for Embedded Ethicists into BRAIN Initiative Supported Research

Notice of Special Interest
Friday, November 19, 2021
Saturday, April 2, 2022
333
NOT-MH-22-040

Funding Opportunity Purpose

The purpose of this Notice of Special Interest (NOSI) is to encourage applications to PA-20-272 to integrate neuroethics perspectives and approaches into existing BRAIN Initiative awards.

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

PAR
Friday, November 19, 2021
Friday, April 19, 2024
U01
PAR-21-343
Debra Babcock

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.

Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional)

PAR
Friday, November 19, 2021
Thursday, December 14, 2023
X02
PAR-21-342

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.

Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61/R33 Clinical Trial Not Allowed)

PAR
Tuesday, November 16, 2021
Friday, March 15, 2024
R61/R33
PAR-22-055

Funding Opportunity Purpose

This FOA invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical research projects, to address scientific and clinical hypotheses relevant to neurological disorders and conditions within the NINDS mission. In this phased funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using Go/No-go data-quality metrics, prior to funding of the second phase of data analyses. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation, and analysis, as well as controlled access to the curated datasets.

HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required)

RFA
Tuesday, November 16, 2021
Saturday, February 12, 2022
R61/R33
RFA-AT-22-003

Funding Opportunity Purpose

The National Institutes of Health (NIH) intends to support the development of innovative quantitative imaging and other relevant biomarkers of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This funding opportunity announcement (FOA) seeks research applications to develop quantitative imaging biomarkers of myofascial tissues and assess their abilities to monitor responses and/or predict outcomes of a variety of pain management regimens. Candidates for the quantitative imaging biomarkers may include objective measures based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors, etc.) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to three years to develop quantitative measures that can differentiate myofascial tissue abnormalities in healthy versus latent, versus active myofascial pain stages using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include team building and planning activities for the R33 phase. The second phase, funded under the R33, will provide up to two years of support to assess the abilities of the quantitative measures developed in the R61 phase to monitor responses and/or predict outcomes in response to specified therapies to relieve myofascial pain in longitudinal interventional studies.

Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed)

Notice of Special Interest
Friday, November 12, 2021
Wednesday, January 8, 2025
R43/R44
NOT-NS-22-017

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive patent license agreement for internal research use for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.

Pages